mostly community-derived Endpoint Wound or scar texture Topical timeline Per-clinician Injectable framing Per-clinician Topical timelines are anchored to published trials
Typical daily range: 2001,000 mcg once daily (gradual titration over 10 weeks)
Treatment plans are individualized and results may vary
Considering the apparent similarity of the animal models and human conditions and the beneficial effects obtained in both in vivo and in vitro experiments, NaBPC157 is useful in an anti-tumor therapy
NaBPC157 In vitro, in gastric mucosa from stomach rat tissue homogenates, NaBPC157 given in the same dose (100 M) as L-arginine, induced a comparable formation of NO
Stable gastric pentadecapeptide BPC 157, roberts stomach cytoprotection/adaptive cytoprotection/organoprotection, and selyes stress coping response: Progress, achievements, and the future